Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma

MAPKAPK2 (MK2), the direct substrate of p38 MAPK, has been well-acknowledged as an attractive drug target for cancer therapy. However, few studies have assessed the functions of it in multiple myeloma (MM). In the present study, MK2 expression of MM patients was analyzed by gene expression profiling...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Front Oncol
Main Authors: Guo, Mengjie, Sun, Dongdong, Fan, Zhimin, Yuan, Yuxia, Shao, Miaomiao, Hou, Jianhao, Zhu, Yuqi, Wei, Rongfang, Zhu, Yan, Qian, Jinjun, Li, Fei, Yang, Ye, Gu, Chunyan
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2019
נושאים:
Oncology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6694709/
https://ncbi.nlm.nih.gov/pubmed/31440466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00722
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים